A multi-national, randomised, open-label, parallel, phase III non-inferiority study comparing NK105 and paclitaxel in metastatic or recurrent breast cancer patients
Open accessThe DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.
Abstract
BACKGROUND: NK105 is a novel nanoparticle drug delivery formulation that encapsulates paclitaxel (PTX) in polymeric micelles. We conducted an open-label phase III non-inferiority trial to compare the efficacy and safety of NK105 and PTX in metastatic or recurrent breast cancer. METHODS: ) on days 1, 8 and 15 of a 28-day cycle. The primary endpoint was progression-free survival (PFS), with a non-inferiority margin of 1.215. RESULTS: A total of 436 patients were randomised and 211 patients in each group were included in the efficacy analysis. The median PFS was 8.4 and 8.5 months for NK105 and PTX, respectively (adjusted hazard ratio: 1.255; 95% confidence interval: 0.989-1.592). The median overall survival and overall response rates were 31.2 vs. 36.2 months and 31.6% vs. 39.0%, respectively. The two groups exhibited similar safety profiles. The incidence of peripheral sensory neuropathy (PSN) was 1.4% vs. 7.5% (≥Grade 3) for NK105 and PTX, respectively. The patient-reported outcomes of PSN were significantly favourable for NK105 (P < 0.0001). CONCLUSIONS: The primary endpoint was not met, but NK105 had a better PSN toxicity profile than PTX. CLINICAL TRIAL REGISTRATION: ClinicalTrials.gov: NCT01644890.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures




Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In July 2016, an open-label phase III non-inferiority trial of NK105 in patients with metastatic or recurrent breast cancer was completed (ClinicalTrials.gov: NCT01644890) [307]. Four hundred thirty-six patients were enrolled in the study and administered either NK105 (65 mg/m2) or conventional paclitaxel (80 mg/m2).”
From Polymeric micelles for the delivery of poorly soluble drugs: From nanoformulation to clinical approval. (2020) · cites this paper as [307]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“The results of the phase III trial revealed that the primary endpoint (statistical non-inferiority of progression-free survival) was not met (the median progression free survival (PFS) of 8.4 and 8.5 months for NK105 and paclitaxel, respectively, and the median overall survival of 31.2 and 36.2 months, and overall response rates of 31.6% and 39.0%, respectively) [307].”
From Polymeric micelles for the delivery of poorly soluble drugs: From nanoformulation to clinical approval. (2020) · cites this paper as [307]
The cited source says what the claim attributes to it.
In the citing paper
“However, the incidence of peripheral sensory neuropathy among patients treated with NK105 was decreased compared to that of paclitaxel, indicating an improved toxicity profile of the drug in NK105 [307].”
From Polymeric micelles for the delivery of poorly soluble drugs: From nanoformulation to clinical approval. (2020) · cites this paper as [307]
In the citing paper
“Fujiwara et al. showed a decrease (81.3%) of the peripheral sensory neuropathy with the use of polymeric micelles loaded with PTX (NK105) in patients with breast cancer (phase III) [25].”
From Biomimetic Magnetoliposomes as Oxaliplatin Nanocarriers: In Vitro Study for Potential Application in Colon Cancer (2020) · cites this paper as [25]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012
Ferlay, J., Soerjomataram, I., Dikshit, R., Eser, S., Mathers, C., Rebelo, M., Parkin, D. M., Forman, D., & Bray, F. (2015) · International Journal of Cancer · doi:10.1002/ijc.29210 · Cited by 28,766
Matsumura, Y., & Maeda, H. (1986) · PubMed · Cited by 6,781
Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review
Maeda, H., Wu, J., Sawa, T., Matsumura, Y., & Hori, K. (2000) · Journal of Controlled Release · doi:10.1016/s0168-3659(99)00248-5 · Cited by 6,565
Paclitaxel plus Bevacizumab versus Paclitaxel Alone for Metastatic Breast Cancer
Miller, K., Wang, M., Gralow, J., Dickler, M., Cobleigh, M., Perez, E. A., Shenkier, T., Cella, D., & Davidson, N. E. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa072113 · Cited by 3,081
Smith, T. J., Khatcheressian, J., Lyman, G. H., Ozer, H., Armitage, J. O., Balducci, L., Bennett, C. L., Cantor, S. B., Crawford, J., Cross, S. J., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.06.4451 · Cited by 1,636
Seidman, A. D., Berry, D., Cirrincione, C., Harris, L., Muss, H., Marcom, P. K., Gipson, G., Burstein, H., Lake, D., Shapiro, C. L., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.11.6699 · Cited by 594
Hamaguchi, T., Matsumura, Y., Suzuki, M., Shimizu, K., Goda, R., Nakamura, I., Nakatomi, I., Yokoyama, M., Kataoka, K., & Kakizoe, T. (2005) · British Journal of Cancer · doi:10.1038/sj.bjc.6602479 · Cited by 565
Gray, R., Bhattacharya, S., Bowden, C., Miller, K., & Comis, R. L. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.21.6630 · Cited by 294
Multicenter Phase II Trial of Weekly Paclitaxel in Women With Metastatic Breast Cancer
Perez, E. A., Vogel, C. L., Irwin, D. H., Kirshner, J. J., & Patel, R. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.22.4216 · Cited by 250
Kato, K., Chin, K., Yoshikawa, T., Yamaguchi, K., Tsuji, Y., Esaki, T., Sakai, K., Kimura, M., Hamaguchi, T., Shimada, Y., et al. (2012) · Investigational New Drugs · doi:10.1007/s10637-011-9709-2 · Cited by 237
Cited by
van der Meel, R., Sulheim, E., Shi, Y., Kiessling, F., Mulder, W. J. M., & Lammers, T. (2019) · Nature Nanotechnology · doi:10.1038/s41565-019-0567-y · Cited by 1,234
Therapeutic Nanoparticles and Their Targeted Delivery Applications
Yetisgin, A. A., Cetinel, S., Zuvin, M., Kosar, A., & Kutlu, O. (2020) · Molecules · doi:10.3390/molecules25092193 · Cited by 1,080
Hwang, D., Ramsey, J. D., & Kabanov, A. V. (2020) · Advanced drug delivery reviews · doi:10.1016/j.addr.2020.09.009 · Cited by 699
The dose threshold for nanoparticle tumour delivery
Ouyang, B., Poon, W., Zhang, Y.-N., Lin, Z. P., Kingston, B. R., Tavares, A. J., Zhang, Y., Chen, J., Valic, M. S., Syed, A. M., et al. (2020) · Nature Materials · doi:10.1038/s41563-020-0755-z · Cited by 514
Application of Nanotechnology in Cancer Diagnosis and Therapy - A Mini-Review
Jin, C., Wang, K., Oppong-Gyebi, A., & Hu, J. (2020) · International Journal of Medical Sciences · doi:10.7150/ijms.49801 · Cited by 353
Metadata
- Authors
- Fujiwara, Y., Mukai, H., Saeki, T., Ro, J., Lin, Y.-C., Nagai, S. E., Lee, K. S., Watanabe, J., Ohtani, S., Kim, S. B., Kuroi, K., Tsugawa, K., Tokuda, Y., Iwata, H., Park, Y. H., Yang, Y., & Nambu, Y.
- Affiliations
- National Cancer Center Hospital (JP)
- National Cancer Center Hospital East (JP)
- Saitama International Medical Center (JP)
- National Cancer Center (KR)
- Chang Gung Memorial Hospital (TW)
- Saitama Cancer Center (JP)
- Shizuoka Cancer Center (JP)
- Hiroshima City Hiroshima Citizens Hospital (JP)
- Asan Medical Center (KR)
- Tokyo Metropolitan Komagome Hospital (JP)
- St. Marianna University School of Medicine (JP)
- Tokai University (JP)
- Aichi Cancer Center (JP)
- Samsung Medical Center (KR)
- China Medical University (TW)
- Nippon Kayaku (Japan) (JP)
- Corresponding author
- Mukai, Hirofumi
- ORCID
- Venue
- British Journal of Cancer
- Published
- 2019-02-12
- Volume
- 120
- Issue
- 5
- Pages
- 475-480
- ISSN
- 0007-0920 (ISSN-L)
- 1532-1827
- PMC
- PMC6461876
- OpenAlex
- W2912831482
- Cited by
- 147
- References
- 18
- Citations by year
- 2026: 25 · 2025: 16 · 2024: 15 · 2023: 22 · 2022: 20 · 2021: 21 · 2020: 20 · 2019: 8
- FWCI
- 7.21
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- Locations
- British Journal of Cancer (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Treatment and Pharmacology
- Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Breast Cancer Treatment Studies
- Keywords
- paclitaxel, metastatic breast cancer, breast cancer recurrence, polymeric micelles, nanoparticle drug delivery, non-inferiority, progression-free survival, peripheral sensory neuropathy, patient-reported outcomes, chemotherapy toxicity
- MeSH terms
- Equivalence Trials as Topic, Progression-Free Survival, Adenocarcinoma, Adult, Aged, Antineoplastic Agents, Phytogenic, Breast Neoplasms, Female, Humans, Middle Aged, Neoplasm Metastasis, Neoplasm Recurrence, Local, Peripheral Nervous System Diseases, Proportional Hazards Models, Paclitaxel
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: A multi-national, randomised, open-label, parallel, phase III non-inferiority study comparing NK105 and paclitaxel in metastatic or recurrent breast cancer patients. https://app.cochat.ai/papers/10.1038/s41416-019-0391-z
- The paper
- Fujiwara, Y., Mukai, H., Saeki, T., Ro, J., Lin, Y.-C., Nagai, S. E., Lee, K. S., Watanabe, J., Ohtani, S., Kim, S. B., Kuroi, K., Tsugawa, K., Tokuda, Y., Iwata, H., Park, Y. H., Yang, Y., & Nambu, Y. (2019). A multi-national, randomised, open-label, parallel, phase III non-inferiority study comparing NK105 and paclitaxel in metastatic or recurrent breast cancer patients. British Journal of Cancer. https://doi.org/10.1038/s41416-019-0391-z
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.